Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Pergoveris versus GONAL-f in poor ovarian response patients undergoing ART
2013-003817-16Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Dec 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in poor ovarian response (POR) comparing Pergoveris arm with GONAL-f arm (2 arms). Primary endpoint: Total number of retrieved oocytes. Started Dec 2013; status: completed.
02
Drugs
luteinizing hormonefollitropin alfa
03
Conditions
poor ovarian response (POR)
Beyond the preview
Go deeper on 2013-003817-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003817-16.